A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies-Reference-Cited by-同舟云学术

A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies

Published:2005-11 Issue:10 Volume:16 Page:1059-1069
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:Anti-Cancer Drugs

Author:

Gu Wen-Zhen,Joseph Ingrid,Wang Yi-Chun,Frost David,Sullivan Gerard M.,Wang Le,Lin Nan-Horng,Cohen Jerry,Stoll Vincent S.,Jakob Clarissa G.,Muchmore Steven W.,Harlan John E.,Holzman Tom,Walten Karl A.,Ladror Uri S.,Anderson Mark G.,Kroeger Paul,Rodriguez Luis E.,Jarvis Kenneth P.,Ferguson Debra,Marsh Kennan,Ng Shichung,Rosenberg Saul H.,Sham Hing L.,Zhang Haiying

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference25 articles.

1. THE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS

2. Sequence dependence of protein isoprenylation

3. Farnesyltransferase Inhibitors

4. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Farnesyl Transferase Inhibitors in an Ageing Model in Drosophila;Journal of Developmental Biology;2023-10-29

2. New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC;Current Signal Transduction Therapy;2011-05-01

3. Discovery of Geranylgeranyltransferase-I Inhibitors with Novel Scaffolds by the Means of Quantitative Structure−Activity Relationship Modeling, Virtual Screening, and Experimental Validation;Journal of Medicinal Chemistry;2009-06-18

4. Delayed rejection of MHC class II-disparate skin allografts in mice treated with farnesyltransferase inhibitors;Transplant Immunology;2009-01

5. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors;Cancer Chemotherapy and Pharmacology;2007-12-06